


FLASCO: The Voice of Oncology in Florida



THE FLORIDA SOCIETY OF CLINICAL ONCOLOGY

2009 FALL MEETING

TAMPA AIRPORT MARRIOTT HOTEL

NOVEMBER 6 - 7, 2009

The Florida Society of Clinical Oncology invites all FLASCO members and oncology health care professionals to our Fall Meeting, being held at the Tampa Airport Marriot Hotel on November 6-7, 2009.

2009– 2010 FLASCO Executive Committee

Gerald Robbins, MD
President

Gerardo Colon-Otero, MD
Vice President

Julio Garcia, MD
Secretary

Alan Marks, MD
Treasurer

Robert Cassell, MD
Imm. Past President

K.S. Kumar, MD
Chm, Bylaws Committee

Thomas Gaddis, MD
Chm, Clinical Practice
Committee

Waseem Khan, MD
Chm, Ethics Committee

Erin Dunbar, MD
Chm, Legislative Committee

Julio Hajdenberg, MD
Chm, Membership Committee

Richard Levine, MD
Chm, Nominating Committee

Jose Lutzky, MD
Chm, Program Committee

Clifford Selsky, MD
Chm, Finance Committee

Randal Henderson, MD
Chm, FCTN Advisory Board

Dorothy Phillips
Executive Director
1 (800) 444-1410 x4410
Dorothy.green@cancer.org

FALL MEETING TOPICS

REGULATORY AND LEGISLATIVE UPDATE

Speaker: Joe Bailes, MD

COLORECTAL CANCER PANEL PRESENTATION

Moderator: Jose Lutzky, MD

Panel Members: Caio Rocha-Lima, MD, Michael Hellinger, MD, Gerald Sokol, MD

FUTURE DRUG DEVELOPMENT:

IT'S IMPACT ON ONCOLOGY CARE

Speaker: To be Announced

HEPARIN INDUCED THROMBOCYTOPENIA

Speaker: Theodore Warkentin, MD

THE FINANCIAL H & P

Speaker: Jeffrey Phipps, II

ASK THE EXPERT SESSION

REIMBURSEMENT, COVERAGE ISSUES, BILLING AND CODING

Speaker: Roberta Buell

TUMOR STAGING REQUIREMENTS & CHANGES:

THE COC AND THE NEW 7TH AJCC EDITION

Speaker: Stephen Hochwald, MD


CONFERENCE GOALS

1. Update participants in recent developments at the national legislative level and on billing and coding issues that may impact the practice of oncology.
2. Provide new information on promising new anticancer agents, on the management of heparin induced thrombocytopenia and on the multidisciplinary management of colorectal cancer.

CONFERENCE OBJECTIVES

At the end of this conference, the participants will be able to:

1. List the most important national legislative issues and their impact on the practice of oncology.
2. State the best management options for patients with localized and metastatic colorectal cancers.
3. List the most promising new anti-cancer agents being currently evaluated.
4. Have a better understanding of the appropriate billing and coding procedures in a medical oncology practice.
5. Recognize the changes in the staging of different malignancies as stated in the 7th AJCC edition.



**2009
Corporate
Members/
Supporters**

**FLASCO
acknowledges the
following
companies as
Corporate
Members/
Supporters of
FLASCO:**

Platinum

- AMGEN
- Astra Zeneca
- Bayer/Onyx
- Celgene
- Cephalon Oncology
- Eli Lilly
- Eisai, Inc.
- Genentech
- GlaxoSmithKline
- Novartis
- Oncology Supply/ION
- Ortho Biotech
- Pfizer Oncology
- Sanofi-Aventis
- The Phipps Wealth Management Group

Gold

- Abraxis Oncology
- Bristol Myers Squibb
- Genomic Health
- Millennium
- Roche
- Wyeth

Silver

- US Oncology
- OSI Pharmaceuticals

Bronze

- Genzyme



HOTEL RESERVATIONS

A block of rooms has been reserved at the Tampa Airport Marriott Hotel. **The FLASCO Executive Director will make all reservations for those wanting to stay at the hotel.** Please indicate arrival/ departure dates on the registration form. The room rate is \$190 per night, including all taxes.

DEADLINES

The Tampa Airport Marriott has requested that all reservations be made prior to **October 9, 2009**. After that date, reservations will only be accepted on a space available and rate available basis.



REGISTRATION

There are no registration fees for FLASCO Members who are current with their 2009 dues.

If you are not a member of FLASCO, your registration fee of \$250 can be applied to a FLASCO membership. Dues are payable annually. Guest fees are listed on the registration form.

Registration forms need to be completed and submitted to FLASCO no later than October 1, 2009.

FLASCO MISSION STATEMENT

The Florida Society of Clinical Oncology is a statewide non-profit organization committed to facilitating and promoting multidisciplinary efforts to improve patient care in Florida by:

- Fostering access to quality cancer care to the citizens of Florida.
- Assisting the cancer practitioners in providing the most cost effective quality care for their patients.
- Acting as an advocate for Florida cancer patients and their families.

**For more information, please contact Dorothy Green Phillips, FLASCO Executive Director
3709 W. Jetton Ave. Tampa, FL 33629 Tel: (813) 349-4410 Fax: (813) 254-5857
Email: dorothy.green@cancer.org FLASCO Website: www.flasco.org**